ERBB2 and breast carcinoma: Ongoing phase II clinical trials (NCT03331601 and NCT03924466) are investigating its efficacy in detecting brain metastases and correlating image-based HER2 quantification with uptake in local or distant metastases in breast cancer patients, respectively (16).